Please assess the completion status of the following clinical trial:

Trial Title: Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age 18 years or older~* Documented metastatic adenocarcinoma of the prostate~* Under active medical oncology care~* ECOG performance status 0 - 3, inclusive~* Able to understand and provide written informed consent~* Able to tolerate the physical requirements of two PET/CT scans including lying for up to 30 minutes~* Progressive disease on any of: bone scan, CT, MRI or serum PSA as judged by the investigator~* Serum prostate specific antigen ≥ 1 ng/ml at baseline or CT/MRI soft-tissue measurable disease as per RECIST v1.1~* Failed, failing, refused, no access to or not eligible for any approved prostate cancer therapies including but not limited to: ADT, NAAD (e.g., abiraterone, enzalutamide, darolutamide or apalutamide), docetaxel, cabazitaxel, radium-223 and oligometastatic RTX~* Life expectancy of at least 3 months as judged by the investigator~Exclusion Criteria:~* Medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)~* Exceeding the weight limit of the PET/CT bed (approximately 400 lbs.) or who cannot fit through the PET/CT bore (approximately 70 cm diameter)~* Unmanageable claustrophobia~* Prior failure of PSMA RLT~* Prior hemi-body irradiation~* Impaired organ function as evidenced by any of the following laboratory values:~  * Absolute neutrophil count \< 1.5 x109/L~ * Platelet count \< 75 x109/L~ * Hemoglobin \< 85 g/L~ * Albumin \< 2.5 g/dL (25 g/L)~ * Total bilirubin \> 2 x ULN (unless in instances of Gilbert's disease)~ * AST or ALT \> 2.5 x ULN (or \> 5.0 x ULN in the presence of liver metastases)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 131I-PSMA-1095 Radioligand Therapy (RLT) (Type: EXPERIMENTAL): Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).